NCT00424840 - Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Lung Cancer

Interventions

DRUG

Bortezomib 1.3 mg/m2

"Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2"

DRUG

Bortezomib 1.6 mg/m2

Level II (every 21 day cycle, D8), 1.6 mg/m2

DRUG

Bortezomib 1.8 mg/m2

Level III (every 21 day cycle, D8) 1.8 mg/m2

DRUG

Carboplatin AUC 6

Carboplatin AUC6

DRUG

Bevacizumab

Bevacizumab 15 mg/kg

DRUG

Taxotere

Taxotere 70 + G-CSF

Trial Locations (1)

01655-0002

University of Massachusetts Medical School, Worcester